As observed in chronic myeloid leukemia (CML) [80], various functional mechanisms have also been postulated to overcome sensitivity to JAK2 inhibitors, representing the most clinically relevant causes of resistance. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.